Navigation Links
NDC Completes Acquisition of Phase One Medical(R) Anchoring Technology
Date:3/2/2009

FREMONT, Calif., March 2 /PRNewswire/ -- Nitinol Devices & Components, Inc. (NDC) announced today that they recently acquired a novel medical device anchoring technology from Phase One Medical, LLC, brokered by Hatch Medical, LLC. This anchoring technology integrates the superelastic material properties of nitinol with proprietary anchoring design elements to provide secure fixation and removability for minimally invasive medical devices. The technology is anticipated to provide a platform for the production of a spectrum of innovative medical device therapies to the cardiovascular surgery and interventional radiology community.

Traditional anchoring technologies include, for example, barbs or hooks in vena cava filters, radial outward forces in endovascular stents, and pinching in atrial septal defect closure devices. Each of these technologies requires significant interaction with the surrounding anatomy such that the native biomechanics are disturbed, at times resulting in negative clinical outcomes. Many of these implantable devices are needed only for a short duration to assist in the natural healing process, after which time the device is no longer necessary and the body could benefit from removal of the device if the biological risks associated with removal are minimal.

The anchoring technology acquired from Phase One Medical offers several key advantages over those conventional technologies while retaining the same small dimensions required to deliver devices using minimally invasive techniques. First, this technology decouples device delivery and anchoring into two separate steps, allowing physicians the opportunity to fully unsheath devices in vivo, position them as necessary, and anchor the devices only after precise placement has been achieved. Second, the anchors may be retracted during the initial implantation procedure even after attachment to the anatomy, thereby providing physicians with multiple opportunities for optimal placement. Next, unlike many medical implants that require several days or weeks for biological tissue ingrowth to assist in the anchoring, the current anchoring technology affixes the device in position without the need of tissue ingrowth, thereby greatly reducing the possibility of migration prior to endothelialization. Finally, when clinically warranted, the anchors are easily removable leaving behind only immediately self-sealing holes smaller than those created by most sutures.

Phase One Medical is a privately held medical device research and development company. The company is focused on development of new and innovative technology supported by generation of strong IP positions. For more information about Phase One Medical, its product licensing history and other active projects visit the company's website at http://www.phaseonemedical.com

NDC is a privately held supplier of nitinol raw materials (wire, sheet, tube, strip and bar), manufacturer of customized components, and offers a wide range of engineering services (mechanical, fatigue and corrosion testing, process development, finite element computer modeling, surface characterization, metallurgical evaluation, and failure analysis) in support of the medical device industry. Their acquisition of the anchoring technology represents an additional medical device incubator endeavor intended to develop innovative implantable therapeutic solutions to challenging clinical problems. This release and additional news about NDC can be obtained by visiting the company's website at: http://www.nitinol.com/


'/>"/>
SOURCE Nitinol Devices & Components, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as ... production of the series is on hiking in American. Viewers can reconnect with America ... great benefits of hiking. , Many consumers have looked for an inventive new place ...
(Date:5/26/2017)... ... ... FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and his faith in ... authors, Bob and Margaret Massey. Bob Massey is small in stature but big in ... His love for others is apparent in all of his life decisions. , ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the ... is the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist ... Jane. Walter. Walter and Jane have three adult children and a granddaughter. ...
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ™, ... has received U.S. Food and Drug Administration (FDA) 510(k) clearance for ... secure cloud platform for medical image management. At the core is patented streaming ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced it has earned a spot ... 2017" list. The Company was ranked among 500 U.S. ... Employers and Healthcare Equipment and Services. The ... on an anonymous, independent survey of over 30,000 employees ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/8/2017)... NEW YORK , May 8, 2017 ... in the transition from fee for service reimbursement. Black ... April 2017. 1.       The Market for ... 77% of physician practices with 3 or ... Compliance Technology Solutions by Q4. "Given the magnitude of ...
Breaking Medicine Technology: